we expect our full year adjusted earnings per share guidance at the high-end of our previous range of $num-one to $num-two.
while public health conditions remain uncertain, we are projecting total sales in the third quarter to grow sequentially to between $num-one billion and $num-two billion resulting in adjusted earnings per share of $num-three to $num-four.
the much stronger than expected sales performance lifted by unexpectedly high procedure volume fell through to the bottom-line resulting in adjusted earnings per share of $num-one.
for total edwards, we now expect sales of $num-one billion to $num-two billion, for tavr $num-three billion to $num-four billion, for tmtt, $num-five million to $num-six million, for surgical structural heart, $num-seven million to $num-eight million, and for critical care, $num-nine million to $num-ten million.
we now expect year-six tmtt sales of $num-one million to $num-two million, up from our previous sales guidance of $num-one million.
we are pleased to report better than expected second quarter sales of $num-one billion, up num-two% on a constant currency basis from a year ago period.
in tavr, second quarter global sales were $num-one million, up num-two% on an underlying basis versus the year ago period or num-three% on a two year compounded annual basis.
for the second quarter, our adjusted gross profit margin was num-one%, compared to num-two% in the same period last year when we experienced lower sales and substantial cost responding to covid.
total sales grew num-one% year-over-year, as patients increasingly were more confident about pursuing treatment in the second quarter.
this quarter, more than num-one patients were treated with sapien valves, an indication that more patients are benefiting from our life changing technologies than ever before.
in critical care, second quarter global sales were $num-one million, up num-two% on an underlying basis versus the year ago period.
in summary, based on the strength that we saw in the second quarter, we have confidence that the underlying tavr sales will grow around num-one% in year-six versus our previous expectation of num-two% to num-one% growth.
we continue to expect our year-six adjusted gross profit margin to be between num-one% and num-two%.
and importantly, sales grew num-one% on a two year compounded annual basis, compared to the strong pre-pandemic second quarter of year-four.
in surgical structural heart, record second quarter global sales of $num-one million was up num-two% on an underlying basis versus a year ago period.
turning to the financial performance in tmtt, global sales of $num-one million were driven by the continued adoption of our pascal platform, as we activated more centers across europe.